Exclusive Content
China Retail Update: Physical Store Sales Rebound 12% — Implications for Distribution Strategy — Key Takeaways
China Retail Update: Physical Store Sales Rebound 12% — Key Implications for Distribution Strategy In 2024, physical store sales in China rebounded 12
China Distribution Update: New E-Commerce Platform Algorithm Penalizes Multi-Channel Sellers — Key Takeaways
China Distribution Update: New E-Commerce Platform Algorithm Penalizes Multi-Channel Sellers — Key Takeaways In late August 2025, the Taobao and Tmall
China Cross-Border E-Commerce Distribution Review: How 1210 and 9610 Models Work for Foreign Brands
China Cross-Border E-Commerce Distribution Review: How 1210 and 9610 Models Work for Foreign Brands body{font-family:Georgia,"Times New Roman",serif;l
B2B China Distributor Platforms Review: Alibaba.com vs Made-in-China vs Global Sources
B2B China Distributor Platforms Review: Alibaba.com vs Made-in-China vs Global Sources body{font-family:Georgia,"Times New Roman",serif;line-height:1.
China’s 2025 Anti-Monopoly Guidelines for Distribution Agreements Review: What Foreign Companies Must Know
China's 2025 Anti-Monopoly Guidelines for Distribution Agreements Review: What Foreign Companies Must Know body{font-family:Georgia,"Times New Roman",
China Biopharma Investment Map 2026: The Big Three Clusters for Foreign Firms
China accounts for 30% of the global drug pipeline. But the opportunity is concentrated in 3 clusters — Yangtze River Delta, Beijing-Tianjin-Hebei, and Greater Bay Area. Here is which cluster fits your business function.